Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies.
Firbank, Michael J
Petrides, George S
Neurobiology of aging
MetadataShow full item record
Mak, E., Donaghy, P. C., McKiernan, E., Firbank, M. J., Lloyd, J., Petrides, G. S., Thomas, A. J., & et al. (2019). Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies.. Neurobiology of aging, 73 74-81. https://doi.org/10.1016/j.neurobiolaging.2018.09.004
Although dementia with Lewy bodies (DLB) is a synucleinopathy, it is frequently accompanied by β-amyloid accumulation (Aβ). Elucidating the relationships of Aβ with grey matter atrophy in DLB may yield insights regarding the contributions of comorbid Alzheimer’s disease to its disease progression. Twenty healthy controls and twenty-five DLB subjects underwent clinical assessment, [18F]-Florbetapir and 3T MRI. Freesurfer was used to estimate cortical thickness and subcortical volumes and PetSurfer was used to quantify [18F]-Florbetapir standardised uptake value ratio. Principal component analysis was used to identify the dominant Aβ component for correlations with regional cortical thickness, hippocampal subfields and subcortical structures. Relative to healthy controls, the DLB group demonstrated increased Aβ in widespread regions encompassing the frontal and temporo-parietal cortices, whereas cortical thinning was restricted to the temporal lobe. Amongst DLB subjects, the Aβ component was significantly associated with more severe hippocampal and subiculum atrophy. These findings may reflect an early process of superimposed AD-like atrophy in DLB, thereby conferring support for the therapeutic potential of anti-Aβ interventions in people with DLB. KEYWORDS: Dementia with Lewy bodies, Alzheimer’s disease, amyloid, PET, MRI.
Hippocampus, Humans, Lewy Body Disease, Alzheimer Disease, Atrophy, Disease Progression, Positron-Emission Tomography, Magnetic Resonance Imaging, Aged, Aged, 80 and over, Middle Aged, Female, Male, Amyloid beta-Peptides
NIHR Newcastle Biomedical Research Centre; Eli Lilly and Company
External DOI: https://doi.org/10.1016/j.neurobiolaging.2018.09.004
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286205